Targeted delivery of a PD-1-blocking scFv by CAR-T cells enhances anti-tumor efficacy in vivo

Cited by (831)

Items 401–500 of 831

1. Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas
   Hao Xu, Ningwen Li, Gaoxiang Wang, Yang Cao · 2023 · Frontiers in Immunology
2. Stalled CARs: Mechanisms of Resistance to CAR T Cell Therapies
   Diego Salas‐Benito, Trisha R. Berger, Marcela Valderrama Maus · 2023 · Annual Review of Cancer Biology
3. Clinical development of chimeric antigen receptor-T cell therapy for hematological malignancies
   Zhihuan Yang, Ying Wang · 2023 · Chinese Medical Journal
4. CAR T cells as micropharmacies against solid cancers: Combining effector T-cell mediated cell death with vascular targeting in a one-step engineering process
   Bianca Altvater, Sareetha Kailayangiri, Christian Spurny, Maike Flügge, Jutta Meltzer, Lea Greune, Katja Urban, Christian Schwöppe, Caroline Brand, Christoph Schliemann et al. · 2023 · Cancer Gene Therapy
5. Rational design of PD-1-CD28 immunostimulatory fusion proteins for CAR T cell therapy
   Theo Lorenzini, Bruno Loureiro Cadilha, Hannah Obeck, Mohamed-Reda Benmebarek, Florian Märkl, Stefanos Michaelides, Thaddäus Strzalkowski, Daria Briukhovetska, Philipp Jie Müller, Sayantan Nandi et al. · 2023 · British Journal of Cancer
6. Research progress of CD80 in the development of immunotherapy drugs
   Lanying Li, Lei Yang, Depeng Jiang · 2024 · Frontiers in Immunology
7. Efficacy and safety of novel multiple-chain DAP-CAR-T cells targeting mesothelin in ovarian cancer and mesothelioma: a single-arm, open-label and first-in-human study
   Tongpeng Xu, Tian Tian, Chen Wang, Xiaofeng Chen, Xiangrong Zuo, Hanyu Zhou, Jian’an Bai, Chenhui Zhao, Shuai Fu, Chongqi Sun et al. · 2024 · Genome Medicine
8. Are chimeric antigen receptor T cells (CAR-T cells) the future in immunotherapy for autoimmune diseases?
   Yeison Santamaría-Alza, Gloria M Vásquez · 2021 · Inflammation Research
9. Driving CAR T Stem Cell Targeting in Acute Myeloid Leukemia: The Roads to Success
   Ilaria Marina Michelozzi, Efstratios Kirtsios, Alice Giustacchini · 2021 · Cancers
10. The Antitumor Activity of CAR-T-PD1 Cells Enhanced by HPV16mE7-Pulsed and SOCS1-Silenced DCs in Cervical Cancer Models
    Jingwei Zheng, Jingsong Huang, Wei Ma, Wenqiang Yang, Bicheng Hu · 2021 · Cancer Management and Research
11. CAR T Cell Therapy’s Potential for Pediatric Brain Tumors
    Pauline Thomas, Natacha Galopin, Emma Bonerandi, Béatrice Clemenceau, Sophie Fougeray, Stéphane Birklé · 2021 · Cancers
12. Engineering T cells to survive and thrive in the hostile tumor microenvironment
    Gloria B. Kim, James L. Riley, Bruce L. Levine · 2021 · Current Opinion in Biomedical Engineering
13. PD-1-CD28 fusion protein strengthens mesothelin-specific TRuC T cells in preclinical solid tumor models
    Stefanie Lesch, Alessia Nottebrock, Felicitas Rataj, Constanze Heise, Stefan Endres, Sebastian Kobold · 2022 · Cellular Oncology
14. Cell-based immunotherapy in gynecologic malignancies
    Bruce T. Schaar, Venkatesh Krishnan, Supreeti Tallapragada, Oliver Dorigo · 2017 · Current Opinion in Obstetrics & Gynecology
15. Beyond PD‐1/PD‐L1: New Immune Checkpoints and Therapeutic Combinations in Cancer Immunotherapy
    Yangyang Li, Zizhen Kang, Yanyun Du · 2026 · Medicine Bulletin
16. Exploration of Tumor Biopsy Gene Signatures to Understand the Role of the Tumor Microenvironment in Outcomes to Lisocabtagene Maraleucel
    N. Eric Olson, Seamus P. Ragan, David J. Reiss, Jerill Thorpe, Yeonhee Kim, Jeremy S. Abramson, Candice McCoy, Kathryn J. Newhall, Brian A. Fox · 2023 · Molecular Cancer Therapeutics
17. Efficacy of programmed cell death 1 inhibitor maintenance after chimeric antigen receptor T cells in patients with relapsed/refractory B-cell non-Hodgkin-lymphoma
    Xiangke Xin, Xiaojian Zhu, Yang Yang, Na Wang, Jue Wang, Jinhuan Xu, Jia Wei, Liang Huang, Miao Zheng, Yi Qun Xiao et al. · 2024 · Cellular Oncology
18. Strategies to Enhance the Efficacy of T-Cell Therapy for Central Nervous System Tumors
    Deepak Upreti, David Bakhshinyan, Darin Bloemberg, Parvez Vora, Chitra Venugopal, Sheila Kumari Singh · 2020 · Frontiers in Immunology
19. T Cell–Mediated Targeted Delivery of Anti–PD-L1 Nanobody Overcomes Poor Antibody Penetration and Improves PD-L1 Blocking at the Tumor Site
    Pierre-Florent Petit, Raphaële Bombart, Pierre-Hubert Desimpel, Stefan Naulaerts, Laurie Thouvenel, Jean‐François Collet, Benoit J. Van den Eynde, Jingjing Zhu · 2022 · Cancer Immunology Research
20. Chimeric antigen receptor-modified T cells therapy in prostate cancer: A comprehensive review on the current state and prospects
    Mingze He, Dongqi Zhang, Yu Cao, Changliang Chi, Zitong Zeng, Xinyi Yang, Guodong Yang, Kritika Sharma, Kebang Hu, Mikhail E. Enikeev · 2023 · Heliyon
21. A promising cancer diagnosis and treatment strategy: Targeted cancer therapy and imaging based on antibody fragment
    Zhao, Xuhong, Ning, Qian, Mo, Zhongcheng, Tang, Shengsong · 2019 · Artificial Cells, Nanomedicine, and Biotechnology
22. Secretion of a VEGF-Blocking scFv Enhances CAR T-cell Potency
    Valentina M. Supper, Hannah Donner, Filippo Birocchi, Alexandra Bratt, Giulia Escobar, Michael C. Kann, Sangwoo Park, Grace Martin, Felix Korell, Hana Takei et al. · 2025 · Cancer Immunology Research
23. RUNX3 improves CAR-T cell phenotype and reduces cytokine release while maintaining CAR-T function
    Xiuxiu Zhu, Wuling Li, Jiadong Gao, Junjie Shen, Yanmin Xu, Chengcheng Zhang, Cheng Qian · 2023 · Medical Oncology
24. Self-assembled nanoparticles: A new platform for revolutionizing therapeutic cancer vaccines
    Tianyu Shi, Mengna Sun, Changchang Lu, Fanyan Meng · 2023 · Frontiers in Immunology
25. Cancer Cell‐Selective PD‐L1 Inhibition via a DNA Safety Catch to Enhance Immunotherapy Specificity
    Shiyi Bi, Wei Chen, Yanyun Fang, Jieyu Shen, Qing Hua Zhang, Hongqian Guo, Huangxian Ju, Ying Liu · 2024 · Angewandte Chemie International Edition
26. CRISPR/Cas9-Mediated Customizing Strategies for Adoptive T-Cell Therapy
    Hyeseon Park, Yoo Kyung Kang, Gayong Shim · 2024 · Pharmaceutics
27. Metabolic Modulation of Kynurenine Based on Kynureninase-Loaded Nanoparticle Depot Overcomes Tumor Immune Evasion in Cancer Immunotherapy
    Se-Youl Chae, Hojeong Shin, J.I. Woo, Seounghun Kang, Soo Min Lee, Dal‐Hee Min · 2024 · ACS Applied Materials & Interfaces
28. Harnessing the tumor microenvironment to boost adoptive T cell therapy with engineered lymphocytes for solid tumors
    Martina Spiga, Elisa Martini, Maria Chiara Maffia, Fabio Ciceri, Eliana Ruggiero, Alessia Potenza, Chiara Bonini · 2024 · Seminars in Immunopathology
29. Lipid metabolic remodeling delays senescence of T cells to potentiate their immunity against solid tumors
    Yemin Xu, Li Ding, Mengyue Wu, Xiya Wang, Lu Wang, Zhou Xu, Yinhe Xia, Zhennan Cao, Yanqing Zhang, Ruilong Song et al. · 2025 · Journal for ImmunoTherapy of Cancer
30. Harnessing the Immune System to Fight Multiple Myeloma
    Jakub Krejcik, Mike Bogetofte Barnkob, Charlotte Guldborg Nyvold, Thomas Stauffer Larsen, Torben Barington, Niels Abildgaard · 2021 · Cancers
31. Cellular transformers for targeted therapy
    Chen Chen, Yuqi Zhang, Zhaowei Chen, Huanghao Yang, Zhen Gu · 2021 · Advanced Drug Delivery Reviews
32. Role of Senescence in Tumorigenesis and Anticancer Therapy
    Ewelina Stoczyńska-Fidelus, Marta Węgierska, Amelia Kierasińska, Damian Ciunowicz, Piotr Rieske · 2022 · Journal of Oncology
33. Beyond direct killing—novel cellular immunotherapeutic strategies to reshape the tumor microenvironment
    Duc Huynh, Pia Winter, Florian Märkl, Stefan Endres, Sebastian Kobold · 2022 · Seminars in Immunopathology
34. Cell-Based Therapies for Solid Tumors: Challenges and Advances
    Anna Smolarska, Zuzanna Kokoszka, Marcelina Naliwajko, Julia Strupczewska, Jędrzej Tondera, Maja Wiater, Roksana Orzechowska · 2025 · International Journal of Molecular Sciences
35. CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
    Reza Elahi, Yassine Alami Idrissi, Anwaar Saeed · 2025 · Cancer Treatment Reviews
36. Therapeutic Advances in Immunotherapies for Hematological Malignancies
    Ayako Nogami, Koji Sasaki · 2022 · International Journal of Molecular Sciences
37. Trends and Technology Development in Life Science
    Dr. Sheeba E · 2023
38. Immunotherapy: breakthrough in Cancer Treatment
    Reshmi Gopalakrishnan, B Thamaraiselvi · 2023
39. Genetically Modified Organisms (GMOs): Balancing Benefits and Ethical Considerations
    V. H. Deepa, Prakriti Pushp · 2023
40. Deletion of CD38 enhances CD19 chimeric antigen receptor T cell function
    Kimberly Veliz, Feng Shen, Olga E. Shestova, Maksim Shestov, Alexander A. Shestov, Sara Sleiman, Tyler Hansen, Roddy S. O’Connor, Saar I. Gill · 2024 · Molecular Therapy Oncology
41. Adoptive immunotherapy with CAR modified T cells in cancer current landscape and future perspectives
    Marta Coscia · 2019 · Frontiers in bioscience
42. Exploiting Ca2+ signaling in T cells to advance cancer immunotherapy
    Xianhui Meng, Xiaoyan Wu, Yuyuan Zheng, Kai Shang, Ruirui Jing, Peng Jiao, Chun Zhou, Jing Zhou, Jie Sun · 2020 · Seminars in Immunology
43. Unique aspects of adaptive immunity in camelids and their applications
    Swarali S. Kulkarni, Darryl Falzarano · 2021 · Molecular Immunology
44. Adhesion analysis via a tumor vasculature-like microfluidic device identifies CD8+ T cells with enhanced tumor homing to improve cell therapy
    Camila P. Camargo, Abir K. Muhuri, Yunus Alapan, Lauren F. Sestito, Megha Khosla, Margaret Patricia Manspeaker, Aubrey S. Smith, Chrystal Mary Paulos, Susan Napier Thomas · 2023 · Cell Reports
45. Utilization of artificial circular RNAs as miRNA sponges and anti-PD-1 scFv expression platforms to suppress hepatocellular carcinoma progression
    Yongping Lai, Fei Wang, Cai Guang, Yingying Li, Jiaxin Weng, Feifan Cai, Leijie Cai, Niangmei Cheng, Bixing Zhao, Yongyi Zeng · 2025 · Frontiers in Immunology
46. Enhancing CAR-T Cell Metabolic Fitness and Memory Phenotype for Improved Efficacy against Hepatocellular Carcinoma
    Jinqi You, Xinyi Yang, Jingjing Zhao, Hao Chen, Yan Tang, Dijun Ouyang, Yuanyuan Liu, Yan Wang, Songzuo Xie, Yuanyuan Chen et al. · 2025 · International Journal of Biological Sciences
47. Recent advances in CAR-MSCs: the new engine of cellular immunotherapy evolution
    Ying Chen, Jing Li, Yingying Ma, Jianjun Fang, Yang Yang, Lun Yan, Xi Zhang, Cheng Zhang · 2025 · Journal of Hematology & Oncology
48. Barriers and Strategies to Enhance CAR ‐T Cell Infiltration in Solid Tumours: A Systematic Review
    Yan Zhang, Huihui Sun, Lianfeng Zhao, Ningning Zhao, 陈政良, Lingfeng He, Zhigang Guo, Jun Yu · 2026 · Immunology
49. Unleashing CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy
    Zhiwei Zhang, Dawei Cui, Hao Wang, Liming Wu, Xia Liu · 2026 · Cancer Immunology Immunotherapy
50. Combination of T cell-redirecting strategies with a bispecific antibody blocking TGF-β and PD-L1 enhances antitumor responses
    Antonio Tapia‐Galisteo, Iñigo Sánchez-Rodríguez, Javier Narbona, Patricia Iglesias-Hernández, Saray Aragón-García, Anaïs Jiménez-Reinoso, Marta Compte, Shaukat Ali Khan, Takeshi Tsuda, Patrick Chames et al. · 2024 · OncoImmunology
51. Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
    Xintong Li, Yuanxin Liu, Jun Gui, Lu Gan, Jianxin Xue · 2024 · Advanced Science
52. Advancing Immunotherapy in Pancreatic Cancer: A Brief Review of Emerging Adoptive Cell Therapies
    Deepak Sherpally, Ashish Manne · 2025 · Cancers
53. The next innovations in chimeric antigen receptor T cell immunotherapies for cancer
    Kusala Anupindi, Julia Malachowski, Isabella Hodson, Daniel Zhu, Carl H. June, Bruce L. Levine · 2025 · Cytotherapy
54. Switching on the green light for chimeric antigen receptor T‐cell therapy
    Sherly Mardiana, Junyun Lai, Imran G. House, Paul A. Beavis, Phillip Kevin Darcy · 2019 · Clinical & Translational Immunology
55. Strategies to Improve Chimeric Antigen Receptor Therapies for Neuroblastoma
    Piamsiri Sawaisorn, Korakot Atjanasuppat, Usanarat Anurathapan, Somchai Chutipongtanate, Suradej Hongeng · 2020 · Vaccines
56. Chimeric Antigen Receptor (CAR)-Modified Immune Effector Cell Therapy for Acute Myeloid Leukemia (AML)
    Utkarsh H. Acharya, Roland B. Walter · 2020 · Cancers
57. CAR-T Cells Shoot for New Targets: Novel Approaches to Boost Adoptive Cell Therapy for B Cell-Derived Malignancies
    Katsiaryna Marhelava, Marta Krawczyk, Małgorzata Firczuk, Klaudyna Fidyt · 2022 · Cells
58. Enhancing adoptive T cell therapy for solid tumor with cell-surface anchored immune checkpoint inhibitor nanogels
    Xingye Chen, Mengqian Gao, Shan An, Lei Zhao, Wenqing Han, Wenjun Wan, Jin Chen, Siqi Ma, Wenhua Cai, Yanni Cao et al. · 2022 · Nanomedicine Nanotechnology Biology and Medicine
59. Precision Agriculture
    Agriculturist, Raj Nivas, 661, 5thMain, 7thCross, BEL layout, 3rd Block Vidyaranyapura, Bengaluru - 97, Dr. Kavitha. S. Raj · 2023
60. Tislelizumab augment the efficacy of CD19/22 dual‐targeted chimeric antigen receptor T cell in advanced stage relapsed or refractory B‐cell non‐Hodgkin lymphoma
    Ying Zhang, Hongzhi Geng, Liangyu Zeng, Jiaqi Li, Qin Yang, Sixun Jia, Xiangping Zong, Wenzhi Cai, Shuangzhu Liu, Yutong Lu et al. · 2023 · Hematological Oncology
61. Beyond CAR T cells: Engineered Vγ9Vδ2 T cells to fight solid tumors
    Chirine Rafia, Christelle Harly, Emmanuel Scotet · 2020 · Immunological Reviews
62. Functional bionanomaterials for cell surface engineering in cancer immunotherapy
    Sheng Ma, Yudi Xu, Wantong Song · 2021 · APL Bioengineering
63. NextGen cell-based immunotherapies in cancer and other immune disorders
    Camillia S. Azimi, Qizhi Tang, Kole T. Roybal, Jeffrey A. Bluestone · 2019 · Current Opinion in Immunology
64. Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s
    DeRenzo, Christopher, Gottschalk, Stephen · 2020 · Advances in Experimental Medicine and Biology
65. Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC
    Jing Chen, Yaser Alduais, Baoan Chen · 2021 · Cell Transplantation
66. Siglec-15 Promotes Evasion of Adaptive Immunity in B-cell Acute Lymphoblastic Leukemia
    Claire E. Pillsbury, Jodi Dougan, Jennifer L. Rabe, Jairo Andrés Fonseca, Chengjing Zhou, Alyssa N. Evans, Hasan Abukharma, Ona Ichoku, Gloria Gonzalez-Flamenco, Sunita I. Park et al. · 2023 · Cancer Research Communications
67. Chimeric antigen receptor T cells in the treatment of osteosarcoma (Review)
    Tong Yu, Weibo Jiang, Yang Wang, Ying Yin Zhou, Jianhang Jiao, Minfei Wu · 2024 · International Journal of Oncology
68. CAR-T cell therapy in advanced thyroid cancer: from basic to clinical
    Zhenhua Sun, Chaohui Wang, Yuyang Zhao, Qingyi Ling · 2024 · Frontiers in Immunology
69. CAR-T cell technologies that interact with the tumour microenvironment in solid tumours
    Chelsea Alice Taylor, Maya Glover, John F. Maher · 2024 · Expert Review of Clinical Immunology
70. Cell Surface‐Tethered Nucleic Acid Therapeutics Program Robust and Tumor‐Responsive Enhancement of Adoptive Cell Therapy
    Mengqian Gao, Yingyu Liu, Lei Zhao, Jin Chen, Wenjun Wan, Ze Yuan, Lingyu Li, Yulun Huang, Yajun Wang, Yiran Zheng · 2025 · Advanced Materials
71. Recent advances and challenges of cellular immunotherapies in lung cancer treatment
    Chengfei Yang, Yue Liu, Ziqi Huang, Sijin Liu, Xi Zhang, Quanxing Liu, Jigang Dai · 2025 · Experimental Hematology and Oncology
72. Natural Killer Cell‐Mediated Antitumor Immunity: Molecular Mechanisms and Clinical Applications
    Nanzhi Luo, Cong Chen, Wenjing Zhou, Jianqi Hao, Song He, Yu Liu, Yin Ku, Linhua Huang, Chuanfen Zhang, Yueli Shu et al. · 2025 · MedComm
73. Enhancing CAR T cell efficacy: the next step toward a clinical revolution?
    Manjusha Namuduri, Renier J. Brentjens · 2020 · Expert Review of Hematology
74. SJI 2020 special issue: A catalogue of Ovarian Cancer targets for CAR therapy
    Emmanuelle Benard, Nicholas Paul Casey, Else Marit Inderberg, Sébastien Wälchli · 2020 · Scandinavian Journal of Immunology
75. Payload Delivery: Engineering Immune Cells to Disrupt the Tumour Microenvironment
    Daniel W. Fowler, Callum Baird Nattress, Alba Southern, Marta Barisa, Jonathan P.H. Fisher · 2021 · Cancers
76. Regulation of CD19 CAR-T cell activation based on an engineered downstream transcription factor
    Duško Lainšček, Anja Golob-Urbanc, Veronika Mikolič, Jelica Pantović-Žalig, Špela Malenšek, Roman Jerala · 2023 · Molecular Therapy — Oncolytics
77. BCMA CAR-T cells in multiple myeloma–ready for take-off?
    Lukas Scheller, Erius Tebuka, Peter Rambau, Hermann Einsele, Michael Hudecek, Sabrina Prommersberger, Sophia Danhof · 2023 · Leukemia & lymphoma/Leukemia and lymphoma
78. CARs of the future
    Anthony F. Daniyan, Renier J. Brentjens · 2019 · American Journal of Hematology
79. Intelligent cell-based therapies for cancer and autoimmune disorders
    Rui Chen, Jing Ji, Stefan K. Siwko, Yun Huang, Yubin Zhou · 2020 · Current Opinion in Biotechnology
80. Characterization of a single chain variable fragment of nivolumab that targets PD-1 and blocks PD-L1 binding
    Jong Shin, Paul J. Phelan, Ole V. Gjoerup, William W. Bachovchin, Peter A. Bullock · 2020 · Protein Expression and Purification
81. Enhancement of the antitumor effect of HER2‐directed CAR‐T cells through blocking epithelial‐mesenchymal transition in tumor cells
    Peng‐Fei Zhang, Yong Huang, Xiao Liang, Dan Li, Lin Jiang, Xiao Yang, Min Zhu, Hongfeng Gou, Youling Gong, Yu‐Quan Wei et al. · 2020 · The FASEB Journal
82. Predicting Responses to Checkpoint Inhibitors in Lymphoma: Are We Up to the Standards of Solid Tumors?
    Ah‐Reum Jeong, Edward David Ball, Aaron Michael Goodman · 2020 · Clinical Medicine Insights Oncology
83. Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer
    Caili Xu, Dianwen Ju, Xuyao Zhang · 2022 · Antibody Therapeutics
84. Synthetic Biology and Biomaterials Strategies to Deceive the Tumor Microenvironment in CAR‐T Immunotherapy
    Grazia Marsico, Sudarshan GC, Velia Siciliano · 2025 · Small
85. Engineering scFv immunotherapies: From CAR T cells to bispecific antibodies
    Mohammad Chand Jamali, Amged Gaffer Mostafa Gaffer, Hakeem Ghani Hassan, Sana Ali, Mahaboob Khan Sulaiman, Anam Tariq, Nasrin Mansuri, Ashit Kumar Dutta, Mustafa Mudhafar · 2025 · International Immunopharmacology
86. Fine tuning towards the next generation of engineered T cells
    Thi Tham Nguyen, Patrick Ho, Sarah Staudt, Céline Grégoire, Kai Ziegler-Martin, Mégane Jassin, Alix Block, Michael Hudecek, Jan Joseph Melenhorst, Jo Caers et al. · 2025 · Nature Biomedical Engineering
87. Turning tumor cells into microvesicles as personalized cancer vaccines for cancer prevention and treatment
    Yuxin Guo, Xinping Zhang, Shao-Zhe Wang, Yin Xu, Hao‐Ran Jia, Ya‐Xuan Zhu, Shun‐Yu Wu, Xiaodong Zhang, Hui‐Heng Feng, Ge Gao et al. · 2024 · Nano Today
88. Muc16CD is a novel CAR T cell target antigen for the treatment of pancreatic cancer
    Heather K. Lin, Dejah A. Blake, Tongrui Liu, Ruby Freeman, Gregory B. Lesinski, Lily P H Yang, Sarwish Rafiq · 2024 · Molecular Therapy Oncology
89. Development of a CD39 nanobody and its enhancement to chimeric antigen receptor T cells efficacy against ovarian cancer in preclinical studies
    Yuchen Zhang, Xian-Yang Li, Qi Deng, Yan-Jun Ge, Ruirong Yi, Huajing Wang, Jian-Tao Wang, Hui Zhou, X L Kong, Rong-Jiao Liu et al. · 2024 · Theranostics
90. Chimeric Antigen Receptor Cell Therapy: Empowering Treatment Strategies for Solid Tumors
    Tang‐Her Jaing, Yi-Wen Hsiao, Yi-Lun Wang · 2025 · Current Issues in Molecular Biology
91. Current status and hurdles for CAR-T cell immune therapy
    Ruocong Zhao, Yuanbin Cui, Shanglin Li, Le Qin, Peng Li · 2019 · Blood Science
92. TRAIL-R1-Targeted CAR-T Cells Exhibit Dual Antitumor Efficacy
    Yaru Nai, Li Du, Meiying Shen, Tingting Li, Jingjing Huang, Xiaojian Han, Feiyang Luo, Wang Wang, Da Pang, Aishun Jin · 2021 · Frontiers in Molecular Biosciences
93. CAR-T cell Therapies for B-cell Lymphoid Malignancies
    Yenny Alejandra Moreno Vanegas, Razan Mohty, Martha E. Gadd, Yan Luo, Mahmoud Deeb Aljurf, Hong Qin, Mohamed A. Kharfan‐Dabaja · 2022 · Hematology/Oncology and Stem Cell Therapy
94. Multi-targeted immunotherapeutics to treat B cell malignancies
    M. Tommy Gambles, Jiyuan Yang, Jindŕich Kopec̆ek · 2023 · Journal of Controlled Release
95. Immune cells in the B-cell lymphoma microenvironment: From basic research to clinical applications
    Wenli Zhang, Mengmeng Liu, Wei Li, Yongping Song · 2024 · Chinese Medical Journal
96. Recent progress in chimeric antigen receptor therapy for acute myeloid leukemia
    Xiangyu Wang, Yanming Zhang, Shengli Xue · 2024 · Annals of Hematology
97. Making Potent CAR T Cells Using Genetic Engineering and Synergistic Agents
    Chi Hoon Park · 2021 · Cancers
98. Car-T Cell Therapy: Current Advances and Future Research Possibilities
    Manal Mohamed Elsayed Ahmed · 2021 · Journal of Scientific Research in Medical and Biological Sciences
99. Why Immunotherapy Fails in Multiple Myeloma
    Luis Gerardo Rodríguez‐Lobato, Aina Oliver‐Caldés, David Fernando Moreno, Carlos Fernández de Larrea, Joan Bladé · 2020 · Hemato
100. Adventures in the Classroom Creating Role-Playing Games Based on Traditional Stories for the High School Curriculum
     Csenge Virág Zalka · 2012 · Digital Commons - East Tennessee State University (East Tennessee State University)